Wells Fargo & Company Lowers Humana (NYSE:HUM) Price Target to $290.00

Humana (NYSE:HUM) had its target price lowered by Wells Fargo & Company from $387.00 to $290.00 in a research note issued to investors on Monday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the insurance provider’s stock.

A number of other research firms have also weighed in on HUM. Oppenheimer cut their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Barclays boosted their price objective on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial dropped their target price on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a report on Friday, October 11th. Stephens reissued an “equal weight” rating and set a $250.00 target price on shares of Humana in a research report on Wednesday, October 9th. Finally, Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana has an average rating of “Hold” and a consensus price target of $315.86.

Humana Trading Up 10.8 %

HUM stock opened at $288.69 on Monday. The company has a market capitalization of $34.76 billion, a price-to-earnings ratio of 25.57, a PEG ratio of 1.98 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a 1-year low of $213.31 and a 1-year high of $527.18. The business has a 50 day simple moving average of $291.98 and a two-hundred day simple moving average of $333.24.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Research analysts anticipate that Humana will post 16.15 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Institutional Investors Weigh In On Humana

Several large investors have recently modified their holdings of HUM. Creative Financial Designs Inc. ADV boosted its stake in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. CarsonAllaria Wealth Management Ltd. boosted its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares in the last quarter. Atwood & Palmer Inc. purchased a new position in shares of Humana in the 3rd quarter valued at $29,000. Ashton Thomas Securities LLC bought a new position in shares of Humana in the 3rd quarter worth $31,000. Finally, Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.